Molecular Partners’ Post

FINALLY! https://lnkd.in/diJbCUcg Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer, Offers Potential for Targeted Therapy #snmmi #PET #NUCLEARMEDICINE #MEDULLARY #THYROID #CANCER

🦠 Read the excerpt from Keosys' free eBook, "An Introduction to Peptide Receptor Radionuclide Therapy" - What is PRRT and Which Conditions Does it Benefit? 👇 https://hubs.li/Q026nvtP0 #medicalimaging #oncology #PRRT

ctDNA Assays: Exploring Their Clinical Use in Oncology Care #crcsm #ASCO #ctDNA #oncology #biomarker #molecularprofiling #colorectalcancer #getpersonal #colorectalcancercanada

Hear from Louise Brackenbury Science Director for Discovery | Charles River, on why she is excited about the potential of liquid biopsy in the world of oncology. Check out her insights and learn more about the future of cancer detection and treatment in this fascinating article from our EUREKA Dose of Science blog #oncology #cancerresearch #liquidbiopsy #lifeatcrl

New year, new trends. One thing to keep an eye on this year will be #LiquidBiopsy testing. Liquid biopsies are a non-invasive, low-cost testing method that could help make #cancer testing and diagnosis more accessible. As it becomes more popular, it will also help to drive the expansion of #PrecisionMedicine in oncology. The more precise we can be, the better. #Oncology #OncologyTrends

Bayer initiates phase I study with novel targeted radionuclide therapy 225Ac-PSMA-Trillium in advanced metastatic prostate cancer

How to fully untap the #anti_tumoral potential of #siRNA? Scientists have come up with a smart way to #deliver this drug modality to tumor cells by optimizing the divalent lipid-conjugated siRNAs for in situ binding to albumin. A preclinical proof of concept was achieved in a model of orthotopic triple negative breast cancer (TNBC) tumors, where the Lead molecule showed greater PK/PD properties than the parent molecule. https://lnkd.in/ehvxYd9u

Our recent publication in the Journal of Clinical Oncology, featuring START’s Dr. Amita Patnaik, MD, FRCPC, highlights the development of QTX3034, a highly-selective, non-covalent, orally bioavailable multi-KRAS inhibitor. This innovative treatment shows potent activity against several #KRAS variants, particularly G12D, and has demonstrated significant tumor growth inhibition in preclinical studies. The leadership of our Principal Investigators and their expertise in KRAS inhibitors continue to push the boundaries of oncology, bringing new hope to patients with challenging cancer types.    Learn more about how we're pioneering clinical trials and advancing cancer therapies. https://lnkd.in/e2nrGnT4 #CancerResearch #Oncology #KRASInhibitors #ClinicalTrials

"32% reduction in risk of recurrence, progression events or mortality when compared to chemotherapy alone." A clinical trial has shown that there's better efficacy when durvalumab is used in combination with a neoadjuvant chemotherapy versus chemotherapy alone, in management of non-small cell lung cancer. Learn more: https://lnkd.in/defnTiAb #afripharmareview #biopharmaceuticals #oncology

Huge news in the field of Cell Therapy today with the FDA approval of the first ever engineered T cell receptor (TCR) T cell therapy by Adaptimmune to treat patients suffering with synovial sarcoma solid tumors. Given the diversity of the human TCR repertoire that consists of billions of distinct TCR clonotypes, to find a specific, potent and safe TCR-T cell treatment and scale it up ready for personalized cancer treatments in the clinic is a major scientific milestone Congratulations to everyone involved at Adaptimmune and the patients, caregivers, investigators, and clinical teams 👏 https://lnkd.in/eTScQTfa